AARTIDRUGS

Aarti Drugs Share Price

 

 

Invest in Aarti Drugs with 3.04X leverage

Invest with MTF

Performance

  • Low
  • ₹366
  • High
  • ₹379
  • 52 Week Low
  • ₹312
  • 52 Week High
  • ₹564
  • Open Price₹376
  • Previous Close₹376
  • Volume102,127
  • 50 DMA₹411.60
  • 100 DMA₹433.89
  • 200 DMA₹446.79

Investment Returns

  • Over 1 Month -3.92%
  • Over 3 Month -28.27%
  • Over 6 Month -31.06%
  • Over 1 Year -11.1%

Smart Investing Starts Here Start SIP with Aarti Drugs for Steady Growth!

Invest Now

Aarti Drugs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 17
  • PEG Ratio
  • 0.6
  • Market Cap Cr
  • 3,377
  • P/B Ratio
  • 2.3
  • Average True Range
  • 10.98
  • EPS
  • 21.81
  • Dividend Yield
  • 0.3
  • MACD Signal
  • -9.26
  • RSI
  • 30.62
  • MFI
  • 16.48

Aarti Drugs Financials

Aarti Drugs Technicals

EMA & SMA

Current Price
₹370.05
-5.65 (-1.5%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹389.62
  • 50 Day
  • ₹411.60
  • 100 Day
  • ₹433.89
  • 200 Day
  • ₹446.79

Resistance and Support

371.58 Pivot Speed
  • R3 389.27
  • R2 383.88
  • R1 376.97
  • S1 364.67
  • S2 359.28
  • S3 352.37

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Aarti Drugs Ltd. is a leading Indian pharmaceutical company specializing in Active Pharmaceutical Ingredients (APIs), formulations, and intermediates. It operates in therapeutic segments like antibiotics, anti-diabetics, and cardiovascular, serving global markets with over 50% of revenue from exports.

Aarti Drugs has an operating revenue of Rs. 2,476.66 Cr. on a trailing 12-month basis. An annual revenue de-growth of -5% needs improvement, Pre-tax margin of 9% is okay, ROE of 12% is good. The company has a reasonable debt to equity of 21%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 59 which is a POOR score indicating inconsistency in earnings, a RS Rating of 41 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 69 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Aarti Drugs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-07 Quarterly Results
2025-07-18 Quarterly Results
2025-05-06 Audited Results
2025-01-29 Quarterly Results & Interim Dividend
2024-10-24 Quarterly Results
Date Purpose Remarks
2025-02-04 INTERIM Rs.1.00 per share(10%)Interim Dividend
2024-02-06 INTERIM Rs.1.00 per share(10%)Interim Dividend
2023-02-08 INTERIM Rs.1.00 per share(10%)Interim Dividend
2022-02-10 INTERIM Rs.1.00 per share(10%)Interim Dividend
View Aarti Drugs Dividend History Arrow

Aarti Drugs F&O

Aarti Drugs Shareholding Pattern

55.03%
10.03%
0.08%
2.15%
0%
23.43%
9.28%

About Aarti Drugs

  • NSE Symbol
  • AARTIDRUGS
  • BSE Symbol
  • 524348
  • Managing Director
  • Mr. Rashesh C Gogri
  • ISIN
  • INE767A01016

Similar Stocks to Aarti Drugs

Aarti Drugs FAQs

Aarti Drugs share price is ₹370 As on 24 January, 2026 | 04:05

The Market Cap of Aarti Drugs is ₹3377.4 Cr As on 24 January, 2026 | 04:05

The P/E ratio of Aarti Drugs is 17 As on 24 January, 2026 | 04:05

The PB ratio of Aarti Drugs is 2.3 As on 24 January, 2026 | 04:05

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23